TERMINATED

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Description

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Conditions

Atopic Dermatitis
Talk to us

Related Conditions:

Atopic Dermatitis

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Fort Smith

Johnson Dermatology, Fort Smith, Arkansas, United States, 72916

North Little Rock

Arkansas Research Trials, North Little Rock, Arkansas, United States, 72217

Los Angeles

Dermatology Research Associates, Los Angeles, California, United States, 90045

Hollywood

Encore Medical Research, Hollywood, Florida, United States, 33024

Winter Park

Conquest Research, Winter Park, Florida, United States, 32789

Owensboro

Allergy and Asthma Specialist, Owensboro, Kentucky, United States, 42301

Troy

Revival Research Institute, LLC, Troy, Michigan, United States, 48084

Portsmouth

ActivMed Practices & Research, Inc., Portsmouth, New Hampshire, United States, 03801

Kenilworth

Metropolitan Dermatology - Clark, Kenilworth, New Jersey, United States, 07033

Portland

Oregon Dermatology and Research Center, Portland, Oregon, United States, 97210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Are candidates for systemic therapy.
  • * Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit:
  • * EASI score greater than or equal to (≥)16
  • * vIGA-AD score ≥3, and
  • * ≥10% of BSA involvement (per EASI BSA).
  • * Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.
  • * Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB.
  • * Are currently being treated with topical or systemic therapy
  • * Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2025-03-14